{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:27:33Z","timestamp":1768508853285,"version":"3.49.0"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Hepatoid adenocarcinoma of the stomach (HAS) is a rare histologic subtype of gastric cancer with distinct pathological features and poor prognosis. Surgery and chemotherapy remain the primary treatment modalities, but outcomes are generally unsatisfactory. Radiotherapy can enhance tumor immunogenicity by releasing tumor antigens, thereby promoting antitumor immune responses and potentiating the efficacy of immune checkpoint inhibitors. We report a case of advanced HAS that progressed after first-line treatment with chemotherapy, immunotherapy, and targeted therapy. The patient subsequently received a combination of radiotherapy, programmed cell death protein 1 (PD-1) blockade, and granulocyte-macrophage colony-stimulating factor (GM-CSF)\u2014termed PRaG therapy. The tumor demonstrated significant shrinkage following PRaG treatment and ultimately achieved pathologic complete response (pCR), with no serious adverse events aside from mild abdominal pain (NRS score 2). This case suggests that PRaG therapy may represent a promising therapeutic approach for patients with metastatic HAS.<\/jats:p>","DOI":"10.3389\/fonc.2025.1726271","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T05:16:47Z","timestamp":1768454207000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Pathologic complete response to PRaG therapy in an elderly patient with refractory metastatic gastric cancer"],"prefix":"10.3389","volume":"15","author":[{"given":"Jun","family":"Lv","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fayi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linjiang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeying","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenghong","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinbiao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuxin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s11596-018-1983-1","article-title":"Clinicopathological characteristics and prognosis of hepatoid adenocarcinoma of the stomach: evaluation of a pooled case series","volume":"38","author":"Zeng","year":"2018","journal-title":"Curr Med Sci"},{"key":"B2","doi-asserted-by":"publisher","first-page":"140587","DOI":"10.1155\/2014\/140587","article-title":"Clinicopathological and prognostic characteristics of hepatoid adenocarcinoma of the stomach","volume":"2014","author":"Yang","year":"2014","journal-title":"Gastroenterol Res Pract"},{"key":"B3","doi-asserted-by":"publisher","first-page":"110591","DOI":"10.1016\/j.ijscr.2024.110591","article-title":"Conversion hepatectomy after chemotherapy including nivolumab for multiple liver metastases of hepatoid adenocarcinoma of the stomach: A case report and literature review","volume":"125","author":"Shiozaki","year":"2024","journal-title":"Int J Surg Case Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2011.12.009","article-title":"Targeting the PD-1\/B7-H1(PD-L1) pathway to activate anti-tumor immunity","volume":"24","author":"Topalian","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.901277","article-title":"GM-CSF: A double-edged sword in cancer immunotherapy","volume":"13","author":"Kumar","year":"2022","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"crossref","DOI":"10.1080\/1750743X.2024.2422813","article-title":"Could senescent cells be the prescription for therapeutic cancer vaccines","volume":"16","author":"Liu","year":"2024","journal-title":"Immunotherapy"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1355566","article-title":"Synergistic antitumor immune response mediated by paclitaxel-conjugated nanohybrid oncolytic adenovirus with dendritic cell therapy","volume":"15","author":"Kim","year":"2024","journal-title":"Front Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13045-022-01242-2","article-title":"Improvement of the anticancer efficacy of PD-1\/PD-L1 blockade via combination therapy and PD-L1 regulation","volume":"15","author":"Wu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.7150\/jca.31435","article-title":"Aberrant AFP expression characterizes a subset of hepatocellular carcinoma with distinct gene expression patterns and inferior prognosis","volume":"11","author":"Chen","year":"2020","journal-title":"J Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/PO-24-00882","article-title":"Serial circulating tumor DNA sequencing to monitor response and define acquired resistance to letrozole\/abemaciclib in endometrial cancer","volume":"9","author":"Konstantinopoulos","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-20-409","article-title":"Circulating tumor DNA as a potential prognostic and predictive biomarker during interventional therapy of unresectable primary liver cancer","volume":"11","author":"Zhao","year":"2020","journal-title":"J Gastrointest Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.705361","article-title":"Immunogenic cell death induction by ionizing radiation","volume":"12","author":"Zhu","year":"2021","journal-title":"Front Immunol"},{"key":"B13","article-title":"Abscopal effect following radiation therapy in cancer patients: A new look from the immunological point of view","volume":"10","author":"Welsh","year":"2020","journal-title":"J BioMed Phys Eng"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2020.0095","article-title":"Radiation-induced abscopal effect and its enhancement by programmed cell death 1 blockade in the hepatocellular carcinoma: A murine model study","volume":"27","author":"Yoo","year":"2021","journal-title":"Clin Mol Hepatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.2229","article-title":"Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors","volume":"36","author":"Luke","year":"2018","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0265","article-title":"Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody","volume":"15","author":"Dewan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3109\/1547691X.2014.880533","article-title":"Norm- and hypo-fractionated radiotherapy is capable of activating human dendritic cells","volume":"11","author":"Kulzer","year":"2014","journal-title":"J Immunotoxicol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cr.7310017","article-title":"Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don\u2019t know","volume":"16","author":"Shi","year":"2006","journal-title":"Cell Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.13943","article-title":"Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial","volume":"312","author":"Hodi","year":"2014","journal-title":"Jama"},{"key":"B21","article-title":"Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy","volume":"8","author":"O\u2019Day","year":"2002","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1726271\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T05:16:48Z","timestamp":1768454208000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1726271\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":21,"alternative-id":["10.3389\/fonc.2025.1726271"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1726271","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]},"article-number":"1726271"}}